China Biologic names CEO

In This List

Blog

Insight Weekly: Loan-to-deposit ratio rises; inventory turnovers ebb; miners add female leaders

Blog

Debt Ceiling Debate: IR Teams Should Prepare for Potential Market Downturns

Blog

Insight Weekly: Sustainable bonds face hurdles; bad loans among landlords; AI investments up

Blog

Insight Weekly: Bank oversight steps up; auto insurers’ dismal year; VC investment slumps

13 Aug, 2018 | 13:48

Author Muhammad Hammad Asif
Theme Healthcare & Pharmaceuticals

Beijing-based biopharmaceutical company China Biologic Products Holdings Inc. appointed Bing Li as its CEO.

Li replaces Zhijun Tong, the blood plasma-based biopharmaceutical company's acting CEO. Tong will continue as an executive director and president of the company.

Li rejoined the China Biologic board on July 25, having previously been a director of the company from February 2011 to May 2014.

The new CEO has experience as managing director of Fosun Group, a China-based international conglomerate and investment company, from March 2016 to December 2017, and a vice president of Shanghai Fosun Pharmaceutical (Group) Co. Ltd., a Chinese pharmaceutical company, from May 2014 to February 2016.